Restriction of third generation cephalosporin use reduces the incidence of Clostridium difficile-associated diarrhoea in hospitalised patients
DOI:
https://doi.org/10.33321/cdi.2003.27.17Keywords:
Staphylococcus aureus, antibiotic resistance, Clostridium difficileAbstract
Third generation cephalosporin antibiotics (3GC) have become the antibiotics of choice in many hospitals in recent years for the treatment of infections such as community-acquired pneumonia. However, increased use of 3GCs has also been associated with a rise in the occurrence of antibiotic-associated diarrhoea due to Clostridium difficile, as well as an increase in the prevalence of antibiotic resistant organisms such as methicillin resistant Staphylococcus aureus, vancomycin resistant enterococci, and extended-spectrum beta-lactamase-producing gram negative bacilli. In Western Australia, greater use of 3GCs was shown to correlate with more Clostridium difficile-associated diarrhoea (CDAD) in a large acute care teaching hospital during the 1980s. During the 1990s, the use of 3GCs in this hospital remained high and/or at the end of 1998, a policy was introduced to prevent the use of ceftriaxone (the only 3GC in use) without prior approval. This resulted in a decline in 3GC use and a 50 per cent reduction in the incidence of CDAD during 1999 and 2000. To strengthen these observations, the impact of the 3GC policy on the occurrence of CDAD was analysed using time-series intervention analysis that showed a statistically significant decrease in the occurrence of CDAD during the post-intervention period after controlling for exogenous factors. Thus, changes in antibiotic prescribing practices can influence the incidence of CDAD and, potentially, antibiotic resistant pathogens. Commun Dis Intell 2003;27 Suppl:S28-S31.
Downloads
References
Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med 1998;49:375-390.
Riley TV. Clostridium difficile: a pathogen of the nineties. Eur J Clin Microbiol Infect Dis 1998;17:137-141.
Borriello SP. Pathogenesis of Clostridium difficile infection. J Antimicrob Chemother 1998;41:13-19.
Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40:1-15.
Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:1027-1034.
Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001;32:1055-1061.
Poxton IR, McCoubrey J, Blair G. The pathogenicity of Clostridium difficile. Clin Microbiol Infect 2001;7:421-427.
Riley TV, Bowman RA, Carroll SM. Diarrhoea associated with Clostridium difficile in a hospital population. Med J Aust 1983;1:166-169.
Riley TV, O'Neill GL, Bowman RA, Golledge CL. Clostridium difficile-associated diarrhoea: epidemiological data from Western Australia. Epidemiol Infect 1994;113:13-20.
Golledge CL, McKenzie T, Riley TV. Extended spectrum cephalosporins and Clostridium difficile. J Antimicrob Chemother 1989;23:929-931.
Thomas C, Stevenson M, Williamson DJ, Riley TV. Clostridium difficile-associated diarrhea: epidemiological data from Western Australia associated with a modified antibiotic policy. Clin Infect Dis 2002;35:1457-1462.
Johnson S, Gerding DN, Olson MM, Weiler MD, Hughes RA, Peterson LR. Prospective controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990;88:137-140.
Zafar AB, Gaydos LA, Furlong WB, Nguyen MH, Mennonna PA. Effectiveness of infection control program in controlling nosocomial Clostridium difficile. Am J Infect Control 1998;26:588-593.
Sanderson PJ. What should we do about patients with Clostridium difficile? J Hosp Infect 1999;43:251-253.
López-Lozano JM, Monnet DL, Yagüe A, Burgos A, Gonzalo N, Campillos P, et al. Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: a time series analysis. Int J Antimicrob Agents, 2000;14:21-31.
Thomas C, Beyaert A, López-Lozano J-M, Stevenson M, Riley TV. Evaluation of a hospital-wide policy restricting 3rd generation cephalosporin use to reduce Clostridium difficile-associated diarrhoea: a time-series analysis. In press.
Riley TV, Codde JP, Rouse IL. Increased length of stay due to Clostridium difficile-associated diarrhoea. Lancet 1995;345:455-456.
Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998;128:989-995.
Ludlam H, Brown N, Sule O, Redpath C, Coni N, Owen G. An antibiotic policy associated with reduced risk of Clostridium difficile-associated diarrhoea. Age Ageing 1999;28:578-580.
Jones EM, Kirkpatrick BL, Feeney R, Reeves DS, MacGowan AP. Hospital-acquired Clostridium difficile diarrhoea. Lancet 1997;349:1176-1177.
McNulty C, Logan M, Donald IP, Ennis D, Taylor D, Baldwin RN, et al. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 1997;40:707-711.
Fukatsu K, Saito H, Matsuda T, Ikeda S, Furukawa S, Muto T. Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus on the incidence of wound infection. Arch Surg 1997;132:1320-1325.
Hill DA, Herford T, Parratt D. Antibiotic usage and methicillin-resistant Staphylococcus aureus: an analysis of causality. J Antimicrob Chemother 1998;42:676-677.
Schentag JJ, Hyatt JM, Carr JR, Paladino JA, Birmingham MC, Zimmer GS, et al. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin Infect Dis 1998;26:1204-1214.
Patterson JE. Antibiotic utilization. Is there an effect on antimicrobial resistance? Chest 2001;119 Suppl 2:S426-S430.
Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584-599.
Cunha BA. Effective antibiotic-resistance control strategies. Lancet 2001;357:1307-1308.
McGowan JE Jr. Strategies for study of the role of cycling on antimicrobial use and resistance. Infect Control Hosp Epidemiol 2000;21 Suppl:S36-S43.
Downloads
Published
How to Cite
License
Copyright (c) 2003 Communicable Diseases Intelligence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
